Revenue was up by 7% to DKK 3,656 million while EBIT improved 11% for an EBIT margin of 33% in the first quarter of the 2015/16 financial year. The results were in line with the company’s expectations.
Coloplast is off to a good start to the financial year, with most European markets showing good results and, notably, with the UK business again contributing to growth. The improvement was due in part to a solid performance by Coloplast’s own UK homecare company after an otherwise difficult year in 2014/2015.
“We’ve had a satisfactory first quarter. One of the reasons our sales have improved is because our UK company has now overcome the challenges of managing electronic prescriptions. We’re winning new and retaining existing customers in the UK market,” said Coloplast CEO Lars Rasmussen.
Sales were up by 8% in Ostomy Care, by 6% in Continence Care, 7% in Urology Care and 10% in Wound & Skin Care. In terms of sales by region, Europe was up 5%, Other Developed Markets grew 6% and Emerging Markets gained 16%.
New product well received by users
The Sensura® Mio Convex ostomy care range has been well received with highly satisfactory user feedback. For the past four months, SenSura® Mio Convex has been available in twelve countries.
“Our new Sensura Mio Convex ostomy care range will come to play a key role in the future, so it is important to us that the users like the new product,” said Mr Rasmussen.
He also mentions the Wound & Skin Care business which has performed well in recent months.
“In the European markets, the Biatain Silicone foam dressing has been the main growth driver,” said Mr Rasmussen.
Coloplast maintains its guidance for the 2015/2016 financial year of 7-8% organic revenue growth at constant exchange rates and of about 7% in DKK. The EBIT margin is expected to be 33-34% at constant exchange rates and 33% in DKK.
For more on the Q1 2015/16 interim report, go to www.coloplast.com/investor.
Press enquiries
Dennis Kaysen
Communication Director
Tel. +45 4911 2608
dkdk@coloplast.com
Investors and financial analysts
Ian Christensen
Vice President, Investor Relations
Tel. +45 4911 1301
dkisec@coloplast.com
